| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
The primary target of 11β-HSD1-IN-12 is 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), a key enzyme in glucocorticoid metabolism. 11β-HSD1 catalyzes the conversion of inactive cortisone to active cortisol, thereby amplifying local glucocorticoid signaling in tissues such as the liver, adipose tissue, and brain. By inhibiting this enzyme, 11β-HSD1-IN-12 reduces intracellular cortisol production and may improve metabolic parameters in conditions of glucocorticoid excess.
|
|---|---|
| ln Vitro |
In vitro data for 11β-HSD1-IN-12 are limited in the available literature. The compound is described as a 11β-HSD1 inhibitor based on its identification in a reference patent. As an inhibitor of this enzyme, it is expected to reduce the conversion of cortisone to cortisol in enzymatic and cellular assays. Further in vitro characterization, including IC50 determination and selectivity profiling against other enzymes, would be required to fully define its activity profile.
|
| ln Vivo |
In vivo data for 11β-HSD1-IN-12 are not extensively reported in the available literature. However, based on its mechanism of action as a 11β-HSD1 inhibitor, the compound is expected to reduce tissue-specific cortisol production and improve metabolic parameters in animal models of obesity and metabolic syndrome. 11β-HSD1 inhibitors have been shown to improve insulin sensitivity, reduce hepatic gluconeogenesis, and attenuate weight gain in preclinical models.
|
| Enzyme Assay |
The in vitro enzyme assay for 11β-HSD1 inhibitors typically involves measuring the conversion of cortisone to cortisol using recombinant human 11β-HSD1 enzyme. The assay is performed in a suitable buffer system (e.g., Tris-HCl, pH 7.4) containing NADPH as a cofactor. Test compounds are incubated with the enzyme and substrate at various concentrations, and the reaction is terminated after a specified incubation period. The amount of cortisol produced is quantified using ELISA, mass spectrometry, or radiometric detection methods. IC50 values are calculated by fitting dose-response curves to the inhibition data.
|
| Cell Assay |
Cellular assays for 11β-HSD1 inhibitors typically use cell lines that endogenously express 11β-HSD1, such as hepatocytes (e.g., HepG2) or adipocytes. Cells are treated with the test compound at various concentrations in the presence of cortisone substrate. After incubation, the conversion of cortisone to cortisol is measured in the cell culture medium using ELISA or LC-MS/MS. The cellular IC50 reflects the compound's ability to inhibit the enzyme in a physiologically relevant cellular context.
|
| Animal Protocol |
In vivo animal studies for 11β-HSD1 inhibitors typically involve oral or intraperitoneal administration of the test compound to rodent models (e.g., mice or rats) that are either healthy or have diet-induced obesity or diabetes. Following treatment, blood and tissue samples are collected to measure cortisol levels, glucose tolerance, insulin sensitivity, and hepatic enzyme expression. The compound's ability to reduce tissue-specific cortisol production and improve metabolic parameters is assessed.
|
| ADME/Pharmacokinetics |
As a small-molecule inhibitor, the pharmacokinetic properties of 11β-HSD1-IN-12 would depend on its physicochemical characteristics. The compound has a molecular weight of 398.95 and a molecular formula of C19H27ClN2O3S. Detailed PK parameters such as half-life, bioavailability, and tissue distribution are not available in the public domain. For research purposes, the compound is typically formulated in suitable vehicles for in vitro and in vivo studies.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for 11β-HSD1-IN-12 in the available literature. As a research chemical, the compound is intended for laboratory use only and should be handled with standard safety precautions. Toxicity studies would be required if the compound were to be developed further for therapeutic applications.
|
| References | |
| Additional Infomation |
11β-HSD1-IN-12 is a 11β-HSD1 inhibitor identified as Example 21 in a reference patent. The compound has a molecular formula of C19H27ClN2O3S and a molecular weight of 398.95. It is used in research on obesity and metabolic syndrome. 11β-HSD1 regenerates active glucocorticoids from inactive forms and is important in regulating intracellular glucocorticoid concentration. The compound is stored under recommended conditions as per the Certificate of Analysis.
|
| Molecular Formula |
C19H27CLN2O3S
|
|---|---|
| Molecular Weight |
398.95
|
| Exact Mass |
398.143
|
| CAS # |
872506-67-7
|
| PubChem CID |
11538562
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.357
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
586
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CCC(NC(C2CCCN(S(C3C=CC=C(Cl)C=3C)(=O)=O)C2)=O)CC1
|
| InChi Key |
ODRPEKCTTLECBX-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C19H27ClN2O3S/c1-14-17(20)10-5-11-18(14)26(24,25)22-12-6-7-15(13-22)19(23)21-16-8-3-2-4-9-16/h5,10-11,15-16H,2-4,6-9,12-13H2,1H3,(H,21,23)/t15-/m0/s1
|
| Chemical Name |
(3S)-1-(3-chloro-2-methylphenyl)sulfonyl-N-cyclohexylpiperidine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5066 mL | 12.5329 mL | 25.0658 mL | |
| 5 mM | 0.5013 mL | 2.5066 mL | 5.0132 mL | |
| 10 mM | 0.2507 mL | 1.2533 mL | 2.5066 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
